Abstract

CDH1 (E-cadherin) bi-allelic inactivation is the hallmark alteration of breast invasive lobular carcinoma (ILC), resulting in its discohesive phenotype. A subset of ILCs, however, lack CDH1 genetic/epigenetic inactivation, and their genetic underpinning is unknown. Through clinical targeted sequencing data reanalysis of 364 primary ILCs, we identified 25 ILCs lacking CDH1 bi-allelic genetic alterations. CDH1 promoter methylation was frequent (63%) in these cases. Targeted sequencing reanalysis revealed 3 ILCs harboring AXIN2 deleterious fusions (n = 2) or loss-of-function mutation (n = 1). Whole-genome sequencing of 3 cases lacking bi-allelic CDH1 genetic/epigenetic inactivation confirmed the AXIN2 mutation and no other cell-cell adhesion genetic alterations but revealed a new CTNND1 (p120) deleterious fusion. AXIN2 knock-out in MCF7 cells resulted in lobular-like features, including increased cellular migration and resistance to anoikis. Taken together, ILCs lacking CDH1 genetic/epigenetic alterations are driven by inactivating alterations in other cell adhesion genes (CTNND1 or AXIN2), endorsing a convergent phenotype in ILC.

Details

Title
Genomic and epigenomic basis of breast invasive lobular carcinomas lacking CDH1 genetic alterations
Author
Dopeso, Higinio 1   VIAFID ORCID Logo  ; Gazzo, Andrea M. 1 ; Derakhshan, Fatemeh 2   VIAFID ORCID Logo  ; Brown, David N. 1 ; Selenica, Pier 1 ; Jalali, Sahar 1 ; Da Cruz Paula, Arnaud 3   VIAFID ORCID Logo  ; Marra, Antonio 1   VIAFID ORCID Logo  ; da Silva, Edaise M. 1   VIAFID ORCID Logo  ; Basili, Thais 1 ; Gusain, Laxmi 1 ; Colon-Cartagena, Lorraine 1 ; Bhaloo, Shirin Issa 1 ; Green, Hunter 1   VIAFID ORCID Logo  ; Vanderbilt, Chad 1 ; Oesterreich, Steffi 4 ; Grabenstetter, Anne 1 ; Kuba, M. Gabriela 1 ; Ross, Dara 1 ; Giri, Dilip 1 ; Wen, Hannah Y. 1 ; Zhang, Hong 1 ; Brogi, Edi 1 ; Weigelt, Britta 1 ; Pareja, Fresia 1   VIAFID ORCID Logo  ; Reis-Filho, Jorge S. 1 

 Memorial Sloan Kettering Cancer Center, Department of Pathology and Laboratory Medicine, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952) 
 Memorial Sloan Kettering Cancer Center, Department of Pathology and Laboratory Medicine, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952); Columbia University, Department of Pathology and Cell Biology, New York, USA (GRID:grid.21729.3f) (ISNI:0000 0004 1936 8729) 
 Memorial Sloan Kettering Cancer Center, Department of Surgery, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952) 
 UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Department of Pharmacology & Chemical Biology, Pittsburgh, USA (GRID:grid.21925.3d) (ISNI:0000 0004 1936 9000) 
Pages
33
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
ISSN
2397768X
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2925318357
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.